Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of BI 1467335
NCT02999191Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PXS-4728A in Nonalcoholic steatohepatitis (NASH) and diabetic retinopathy (DR) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point at 24 hours and Maximum measured concentration of the analyte in plasma at 24 hours. Started Jan 2017; status: completed.
02
Drugs
PXS-4728A
03
Conditions
Nonalcoholic steatohepatitis (NASH)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT02999191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999191.